Remove Clinical Development Remove International Remove Licensing
article thumbnail

Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

The Pharma Data

The two companies — through their respective subsidiaries — have entered into a strategic agreement that aims to accelerate the generation of high-caliber clinical data for TEV-56278 while extending its reach to patients across geographies with high unmet medical need.

article thumbnail

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

The Pharma Data

The strategic funding arrangement is designed to support the continued advancement and global commercialization of Revolution Medicines’ RAS(ON) inhibitor portfolio, including its lead candidate daraxonrasib, as the company scales its operations independently across the international oncology market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Internally, the models learn to associate concepts, find patterns and relate text and images (or other modalities) so that they can be analysed in the same way. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes.

Drugs 65
article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

To date, more than 70 joint research projects have been initiated, and over 10 co-authored publications have appeared in top-tier international academic journals. A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors.

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

One of the most significant challenges in drug development is global regulatory variability. While international agencies strive for harmonization through organizations such as the International Council for Harmonisation (ICH), regulatory frameworks differ significantly across regions.

article thumbnail

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

Donello was most recently Vice President of External Science & Innovation at Allergan/AbbVie, where he led R&D innovation efforts to develop strategic collaborations, in-license clinical-stage assets and evaluate M&A opportunities.

article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

The leading clinical program had been the ADC patritumab deruxtecan (HER3-DXd) targeting HER3 and carrying a topoisomerase I inhibitor payload (Topo1i, the drug conjugate) attached using a cleavable linker. Clinical development is extensive, as detailed by @ByMadeleineA at ApexOnco ( [link] ; [link] ).